UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Waldenström Macroglobulinemia

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e35-e35

Treon, S.P

2015

Volltextzugriff (PDF)

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia

Annals of oncology, 2004-10, Vol.15 (10), p.1481-1483

2004

Volltextzugriff (PDF)

Characterization of familial Waldenstrom's macroglobulinemia

Annals of oncology, 2006-03, Vol.17 (3), p.488-494

2006

Volltextzugriff (PDF)

The Genomic and Transcriptional Landscape of Waldenström’s Macroglobulinemia Impacts Disease Presentation, Overall Survival, and Therapeutic Response

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e43-e44

2015

Volltextzugriff (PDF)

Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

Leukemia, 2014-08, Vol.28 (8), p.1698-1704

2014

Volltextzugriff (PDF)

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

Seminars in hematology, 2023-03, Vol.60 (2), p.107-112

2023

Volltextzugriff (PDF)

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

Seminars in hematology, 2023-03, Vol.60 (2), p.90-96

2023

Volltextzugriff (PDF)

Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling

Leukemia, 2016-05, Vol.30 (5), p.1116-1125

2016

Volltextzugriff (PDF)

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

Leukemia, 2015-12, Vol.29 (12), p.2338-2346

2015

Volltextzugriff (PDF)

Extended rituximab therapy in Waldenström's macroglobulinemia

Annals of oncology, 2005, Vol.16 (1), p.132-138

2005

Volltextzugriff (PDF)

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling

Annals of oncology, 2006-08, Vol.17 (8), p.1275-1282

2006

Volltextzugriff (PDF)

IBRUTINIB MONOTHERAPY PRODUCES LONG‐TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA. FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821)

Hematological oncology, 2019-06, Vol.37 (S2), p.184-185

2019

Volltextzugriff (PDF)

The WHIM-like [CXCR4.sup.S338X] somatic mutation activates AKT and ERK, and promotes resistance to ibratinib and other agents used in the treatment of Waldenstrom's macroglobulinemia

Leukemia, 2015-01, p.169

2015

Volltextzugriff (PDF)

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome

Genes and immunity, 2014-01, Vol.15 (1), p.54-56

2014

Volltextzugriff (PDF)

A PROGNOSTIC SCORE FOR TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA

Hematological oncology, 2019-06, Vol.37 (S2), p.401-403

2019

Volltextzugriff (PDF)

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.235-237

2019

Volltextzugriff (PDF)

PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

HemaSphere, 2019-06, Vol.3 (S1), p.260-261

2019

Volltextzugriff (PDF)

CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines

Blood, 2000-02, Vol.95 (3), p.1039-1046

2000

Volltextzugriff (PDF)

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens

Annals of oncology, 2000, Vol.11 (suppl-1), p.S107-S111

2000

Volltextzugriff (PDF)

CD14 mediated endogenous TNF-alpha release in HL60 AML cells: A potential model for CD14 mediated endogenous cytokine release in the treatment of AML

Leukemia research, 1994, Vol.18 (1), p.17-21

1994

Volltextzugriff (PDF)

Monoclonal antibody therapy in the treatment of Reye's syndrome

Medical hypotheses, 1992-11, Vol.39 (3), p.238-242

1992

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Biological And Medical Sciences
(8)
Macroglobulinemia
(8)
Medical Sciences
(8)
Hematology
(7)
Oncology
(7)
Pharmacology. Drug Treatments
(7)
Antineoplastic Agents
(6)
Mutation
(5)
Rituximab
(5)
Cancer Research
(4)
Female
(4)
Genetic Aspects
(4)
Immunodeficiencies. Immunoglobulinopathies
(4)
Immunoglobulinopathies
(4)
Immunopathology
(4)
Immunotherapy
(4)
Male
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(5)
Leukemia
(4)
Hematological Oncology
(3)
Clinical Lymphoma, Myeloma And Leukemia
(2)
Seminars In Hematology
(2)
Blood
(1)
Genes And Immunity
(1)
Hemasphere
(1)
Leukemia Research
(1)
Medical Hypotheses
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Waldenström Macroglobulinemia

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia

Characterization of familial Waldenstrom's macroglobulinemia

The Genomic and Transcriptional Landscape of Waldenström’s Macroglobulinemia Impacts Disease Presentation, Overall Survival, and Therapeutic Response

Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

Extended rituximab therapy in Waldenström's macroglobulinemia

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling

IBRUTINIB MONOTHERAPY PRODUCES LONG‐TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA. FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821)

The WHIM-like [CXCR4.sup.S338X] somatic mutation activates AKT and ERK, and promotes resistance to ibratinib and other agents used in the treatment of Waldenstrom's macroglobulinemia

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome

A PROGNOSTIC SCORE FOR TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens

CD14 mediated endogenous TNF-alpha release in HL60 AML cells: A potential model for CD14 mediated endogenous cytokine release in the treatment of AML

Monoclonal antibody therapy in the treatment of Reye's syndrome

Suchergebnisse filtern